# C_2014012EN.01000501.xml

| 16.1.2014 | EN | Official Journal of the European Union | C 12/5 |
| --- | --- | --- | --- |

16.1.2014

EN

Official Journal of the European Union

C 12/5

---

Prior notification of a concentration

(Case COMP/M.7114 — JLL/DSM/JV)

Candidate case for simplified procedure

(Text with EEA relevance)

2014/C 12/05

| 1. | On 8 January 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking JLL Patheon Co-Investment Fund, L.P. (‘JLL Holdco’), an affiliate of JLL Partners (‘JLL’) and Koninkijke DSM NV (‘DSM’) will create a joint venture (‘JV’) within the meaning of Article 3(4) of the Merger Regulation through a multi-step transaction and the contribution of certain businesses, assets and cash. |
| --- | --- |

1.

On 8 January 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking JLL Patheon Co-Investment Fund, L.P. (‘JLL Holdco’), an affiliate of JLL Partners (‘JLL’) and Koninkijke DSM NV (‘DSM’) will create a joint venture (‘JV’) within the meaning of Article 3(4) of the Merger Regulation through a multi-step transaction and the contribution of certain businesses, assets and cash.

1

| 2. | The business activities of the undertakings concerned are:






  — | for JLL: private equity firm holding investments in various industries including pharmaceutical contract development and manufacturing outsourcing, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for JLL: private equity firm holding investments in various industries including pharmaceutical contract development and manufacturing outsourcing,

| — | for DSM: a global science-based company active in health, nutrition and materials, |
| --- | --- |

—

for DSM: a global science-based company active in health, nutrition and materials,

| — | for JV: pharmaceutical contract development and manufacturing outsourcing. |
| --- | --- |

—

for JV: pharmaceutical contract development and manufacturing outsourcing.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7114 — JLL/DSM/JV, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.7114 — JLL/DSM/JV, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5 (‘Notice on a simplified procedure’).

2

---